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  In ómós do mo mháthair agus do m’athair,  
   mo bhean agus mo mhac. 

Abstract 
Hutchinson-Gilford progeria syndrome (HGPS) and restrictive dermopathy (RD) are two rare 
genetic disorders that affect children. Complications from cardiovascular disease, including 
atherosclerosis, are the most common cause of  death in HGPS, which occurs at around 13 
years of  age. RD patients seldom live beyond their first few weeks of  life, with their 
characteristically tight skin causing death by restricting respiration.  
These diseases are caused by mutations that cause the accumulation of  prelamin A, or one of  
its truncated forms, prelamin AΔ50 (progerin). The majority of  HGPS cases are due to a de 
novo single point mutation in exon 11 of  the LMNA gene, c.1824C>T (p.G608G). This gene 
encodes the A-type lamins, which are major proteins of  the inner nuclear lamina. Most cases 
of  RD are caused by loss of  function mutations in the lamin A processing zmpste24 enzyme.  
Inducible and tissue specific mouse models were used to examine the mechanistic effects of  
progerin. The mouse models carried an artificial minigene which encoded lamin A with the 
the most common HGPS mutation. This minigene was targeted to the skin in Papers I and II 
by means of  the keratin 5 (K5) promoter, and to the cardiovascular system in Paper III by 
means of  the sm22α promoter.  
In Paper I, the effects of  progerin were examined with a focus on postnatal skin. Our results 
showed a reduced population of  keratinocytes with stem cell properties. This was associated 
with downregulation of  P63 (an epidermal stem cell maintenance protein) in the HGPS mice, 
an effect also found with increased ageing in HGPS patients cells.  
In Paper II, to test the hypothesis that the more severe symptoms in RD, as compared with 
HGPS, are due to the higher levels of  farnesylated lamin A produced in RD, the LMNA c.
1824C>T, p.G608G was expressed in embryonic skin causing early postnatal death, as in the 
human condition. This was accompanied by increased inflammation, prolonged expression 
of  the lamin B receptor gene, and arrested skin development.  
In Paper III a model was designed to examine the effects of  progerin in the cardiovascular 
system. However the expression of  the reverse sm22α transactivator was barely detectable in 
arteries, and this low level of  expression was not sufficient to induce expression of  the target 
human lamin A gene.  
This thesis offers novel findings about the intricate molecular disease mechanisms underlying 
HGPS and RD. 
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1. Introduction 
1.1.	 	 Hutchinson-Gilford Progeria Syndrome 
Hutchinson-Gilford Progeria Syndrome (HGPS, Online inheritance in man 176670 
(OMIM)), is a rare genetic disease causing features suggestive of  premature ageing in 
children. First described in 1886 by Hutchinson, and in 1904 by Gilford,1,2 it was not until 
2003 that the genetic cause of  progeria was found,3,4 a de novo mutation in exon 11 of  the 
paternal allele of  the LMNA gene, c.1824C>T. This silent mutation (G608G), causes no 
change in the resultant amino acid (which remains a Glycine), however it increases the use of  
an aberrant cryptic mRNA splice site, resulting in the production of  a protein known as 
progerin.3,4 Although numerous mutations have now been discovered that cause HGPS 
(Figure 5), this mutation accounts for the vast majority of  HGPS cases. It is the accumulation 
of  progerin that is thought to cause the ageing-pathophysiology of  HGPS. The disease occurs 
in both sexes with a slightly higher incidence in males (1.2:1), and is found across diverse 
biogeographical ancestries seemingly without bias.5  
Children with HGPS appear normal at birth, however during their first years of  life the 
phenotype becomes apparent. The skin is where the symptoms first appear, and appear most 
strikingly, with a scleroderma-like appearance. The children also fail to thrive, showing severe 
growth retardation (Figure 1). 
Figure 1. A child with HGPS. A child, aged seven years old in the picture on the left, and twelve on 
the right, shows the characteristic diminished stature and alopecia of  HGPS.2 
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These symptoms are followed by the development of  a striking aged-like appearance 
revealing itself  with symptoms such as alopecia (hair loss, affecting even the eyebrows), 
prominent forehead and scalp veins. A loss of  subcutaneous fat causes a thin and tight 
appearance of  the skin.6-10  
Not only do these children take on the appearance of  an aged individual, but many ageing-
associated health problems also affect them. The disease affects many organ systems of  the 
body (such as bones, adipose, skin, hair, cardiovascular). Osteolysis, the loss of  bone, occurs as 
the children develop, particularly affecting the distal phalanges and clavicles.6,10-13 Other bone 
abnormalities are seen, such as delayed and abnormal dentition and micrognathia (a small 
jaw). Joint stiffness leading to limited joint mobility also occurs. Some organs seem to be 
completely unaffected, such as the kidney, liver, lung, gastrointestinal tract, bone marrow and 
brain. The patients show normal intelligence and studies on brain reveal no significant disease 
pathology.6,11,12 This segmented tissue specificity of  HGPS is one of  the diseases most 
intriguing characteristics.  
The children with HGPS die at an average age of  approximately 13 years, with over 90% of  
deaths caused by complications due to the progressive atherosclerosis of  the coronary and 
cerebrovascular arteries.14,15 
1.2.	 	 Restrictive Dermopathy 
Restrictive dermopathy (RD, OMIM 275210) is a rare, lethal autosomal congenital disorder. 
It is caused by dominant de novo mutations in the LMNA gene or, more commonly, recessive 
null ZMPSTE24 mutations. The earliest symptoms are intrauterine growth retardation and 
decreased foetal movement. After a usually premature birth the child displays a thin, 
translucent and tight skin, as well as joint contractures and respiratory insufficiency. Other 
symptoms include a small pinched nose, posteriorly rotated and low-set earlobes, lack of  
eyebrows and eyelashes, micrognathia and a mouth fixed in a characteristic ‘o’ shape. Death 
occurs within a few weeks of  birth by respiratory failure due to the tight skin.16,17 
Histology of  the skin revealed thin epidermal layers with regular structure, immature and 
poorly developed sebaceous glands and hair follicles, and a flat epidermal-dermal junction. 
The dermis displayed parallel collagen bundles and almost no elastic fibres.16,18 
Mechanistically RD is thought to be similar to HGPS, with progerin or prelamin A 
accumulation causing the disease. It has been suggested that the more severe effects of  RD 
compared to HGPS correspond with increased levels of  progerin or prelamin A.16,19 
Figure 2. The nuclear envelope (NE) (Opposite page). The nuclear A- and B-type lamins lie under 
the nucleoplasmic side of  the inner nuclear membrane (INM). They provide nuclear stability, an 
organisational binding platform for chromatin, and also facilitate localisation and binding of  a large 
family of  nuclear envelope proteins. Lamina-associated polypeptide 1 and 2, LAP1 and LAP2; Lamin B 
receptor, LBR; LEM domain-containing protein 3, MAN1; Outer nuclear membrane, ONM; 
Perinuclear space, PNS; Nuclear envelope spectrin repeat proteins 1 and 2, Nesprin 1 and Nesprin 2; 
Nuclear pore complex, NPC; SUN, Sad1p and UNC-84 homology.20  
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1.3	 	 The Nucleus, Nuclear Envelope, And The Lamina 
The nucleus is known as the control centre of  the cell, and is the defining characteristic 
organelle of  the eukaryotic cell. It contains the majority of  the cells genetic material, and is 
segregated from the cellular cytoplasm by the bilayer nuclear envelope (NE) (Figure 2). The 
NE consists of  concentric inner and outer nuclear membranes (the INM, and ONM). 
Between the INM and ONM lies the perinuclear space (PNS). The ONM is continuous with 
the rough endoplasmic reticulum (ER), and like the ER it is studded with protein-producing 
ribosomes. Large, complex and heterogeneous protein structures known as nuclear pore 
complexes (NPCs) connect the INM and ONM, and act as selective channels through the 
NE.21,22 
Small molecules under approximately 40 kDa are passively transported through the NPCs. 
Larger molecules such as mRNAs, tRNAs, ribosomes, proteins, lipids, carbohydrates or 
signalling molecules can be actively transported both into and out of  the nucleus.23,24 The 
INM lies directly over, and is connected to, the filamentous proteins of  the nuclear lamina.25 
This thin (30-100nm) structure is a densely woven mesh made primarily of  A-type lamin 
proteins, which are encoded by the LMNA gene, as well as B-type lamins, and lamin 
associated proteins. It plays a major role in both structure, such as determining the size and 
shape of  the nucleus, but also in cellular processes such as DNA replication and transcription.
26-29  
The lamina also play a key role in anchoring proteins to the NE, such as the NPCs, as well as 
binding heterochromatin, chromatin and transcription factors to the nuclear periphery.27,30,31 
The A and B type lamins form distinct but interacting lattices in the nuclear lamina, and 
lamins A and C segregate in vivo, which suggests that lamins form distinct homodimers,32 
although they have been found to form heterodimers in vitro.26  
The cytoskeleton is a dynamic network of  protein fibres which lies in the cytoplasm, and is 
linked to the nucleus by the NE. It is made up of  microtubules, microfilaments and 
intermediate filaments. This structure has a multitude of  functions, such as giving the cell 
shape and resistance to mechanical stress, aiding in cell division and intracellular transport, 
and acting as a scaffold to organise cellular contents (Figure 3).33 
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1.4	 	 Lamins And The LMNA Gene  
The LMNA gene (OMIM: 150330) is composed of  12 exons located on chromosome 1q22 
(Figure 5). By means of  alternative splicing within exon 10 it encodes the major isoforms of A-
type lamins, lamin A and lamin C, as well as the minor isoforms A∆10 and C2. Lamin A/C 
proteins form the majority of  the nuclear lamina, and are mainly expressed in terminally 
differentiated cells, suggesting that they have a role in stabilising differential gene expression.34 
Lamins A and C are identical for the first 566 amino acids, thereafter the C-terminal of  lamin 
A has 98 unique amino acids and ends in a CAAX motif. Lamin C ends instead with a 
unique sequence of  6 amino acids. The second family of  lamins consists of  B-type lamins, 
lamin B1 encoded by the LMNB1 gene, and lamin B2 and B3 encoded by the LMNB2 gene. 
As with lamin A, the B-type lamins have a CAAX motif. However they are constitutively 
farnesylated, whereas lamin A loses its farnesyl group once transported to the lamina (Figure 
6).35 
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Figure 3. A dividing cell. Beta-actin is a component of  the cytoskeleton (blue), 
which gives the cell structure and integrity. The DNA is labelled yellow, and Lamin B1 
in red. Lamin B1 is a component of  the nuclear envelope, as this cell is now entering cell 
division the NE has dispersed.
Figure 4. The lamin filaments. Lamin filaments have a central rod domain, with a small globular 
head domain at the N-terminal, and a large globular tail domain at the C-terminal. Dimers are formed 
by coil-coiled interactions between the rod domains, polymers are then formed by head to tail 
associations, which then in turn associate laterally to form lamin protofilaments. 
1.5	 	 Laminopathies  
Laminopathies are a diverse group of  diseases that are caused by mutations affecting the 
nuclear lamina. There are primary laminopathies, with mutations in the LMNA gene.36 At 
present, 464 different mutations from 2,251 individuals have been found in the LMNA gene.37 
There are also secondary laminopathies, with mutations in genes encoding prelamin A 
processing proteins (such as ZMPSTE24), B-type lamins (LMNB1 and LMNB2), or lamin-
binding proteins (such as EMD, LAP2α, TMPO, LBR and LEMD3).38,39 The mutations can be 
de novo (usually dominant), or heritable (both dominant and recessive), with either a gain- or 
loss-of-function effect. These diseases can also range in severity from minor arrhythmia to the 
neonatally lethal tight skin condition, RD40. Lamin A is expressed in all differentiated cells34, 
and so the segmental phenotypes of  laminopathies is difficult to explain, however there are 
several hypotheses. Allele specific mutations of  LMNA can have different effects, the C-allele 
(of  a single nucleotide variant in exon 10) has been shown to be more frequently expressed. It 
accounts for ~70% of  lamin A and C transcripts. An analysis of  samples from six HGPS 
patients showed that the p.G608G mutation can be located on either allele. This could 
account for the variability in HGPS phenotype, and a similar phenomenon may be 
responsible for the variable phenotype in other laminopathies.41  
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The location of  the mutation on the LMNA gene can also cause a variation in effects, 
mutations in the central conserved α-helical domain cause different effects from mutations 
that cluster at site of  the NLS, affecting nuclear import (Figure 5). Additionally if  a mutation 
lies on exon 11, it can only affect lamin A. However mutations on exon 10 affect both lamin A 
and C, such as in the case of  type-A mandibuloacral dysplasia (MAD, OMIM 248370), a 
lipodystrophy with some aspects of  progeria syndromes.  
The mutations causing laminopathies are pleiotropic, meaning that although they affect only 
one gene, they cause multiple, apparently unrelated phenotypic changes. For example, the 
mutation affecting amino acid 527 of  LMNA, can be mutated to R527H and R527C resulting 
in MAD.42,43 Although one family had two siblings with homozygous instances of  R527C that 
caused HGPS.44 Additionally, the mutation R527P has been found to cause Emery–Dreifuss 
muscular dystrophy (EDMD) (Figure 5).45 Mutations at the LMNA R25 locus have been found 
to cause EDMD, early-onset limb girdle muscular dystrophy, type 1B (LGMD1B), dilated 
cardiomyopathy, type 1A (CDM1A) or Dunnigan familial partial lipodystrophy (FPLD2) 
(Figure 5).  
Different laminopathies can also be caused by the same missense mutation occurring at the 
same locus. For example, S573L in exon 11 of  LMNA in one family gave rise to CDM1A, and 
in another family caused FPLD2. The E358K mutation in LMNA has been identified in 
patients with EDMD, LGMD1B, and congenital muscular dystrophy (MDC) (Figure 5).46 
The same mutation can also cause different diseases, even when having occurred in the same 
family. The single nucleotide deletion at position 959, in exon 6 of  LMNA, has been identified 
as causing one case of  DCM, one of  EDMD and two of  LGMD1B (Figure 5).47 This disease 
heterogeneity indicates that there are other disease modifiers and interacting elements that 
have yet to be discovered in the genomes of  patients with laminopathies.  
Laminopathies can be divided into four categories based on their phenotypes: muscular 
dystrophies (affecting striated muscle), lipodystrophies (affecting adipose tissue), neuropathies 
(affecting peripheral nerves) and segmental progeria syndromes (causing several tissues to 
prematurely age) (Figure 5). Overlapping syndromes also occur, where symptoms from 
multiple categories are found. Segmental progeriod syndromes include HGPS and RD, along 
with MAD, and atypical Werner syndrome (AWS, OMIM 277700). Werner syndrome is 
characterised by features of  premature ageing and cancer, and is known as “progeria of  the 
adult”. The main clinical features in Werner’s syndrome appear in the second or third 
decades of  life, and include scleroderma-like skin, diminished stature, premature joint-stiffness 
and osteoporosis, diabetes and premature thinning of  the hair. Classical Werner’s syndrome is 
caused by mutations in the WRN gene, a member of  the RECQ family of  DNA helicases, 
which are involved in DNA repair.115 
Figure 5. The lamin A gene (Opposite page). Lamin C is encoded by exons 1-9 and a section of  
exon 10. Lamin A is a result of  alternative splicing, using exons 1 to 12, but without the lamin C 
specific part of  exon 10 (lamin C specific amino acids are marked in green). The conserved α-helical 
regions of  the central rod domain are marked with coil 1a, coil 1b, and coil 2. The numbers refer to 
primary sequence locations. Most (>90%) HGPS patients carry the de novo c. 1824C>T, p.G608G 
mutation,3 which is highlighted with a red asterisk, this is the mutation that was expressed in our mouse 
models (Paper I-III). AWS, atypical Werner syndrome; CDM1A, dilated cardiomyopathy, type 1A; 
CMT2B1, Charcot–Marie–Tooth disorder, type 2B1; EDMD, Emery–Dreifuss muscular dystrophy; 
FPLD, Dunnigan familial partial lipodystrophy; HGPS, Hutchinson–Gilford progeria syndrome; 
LGMD1B, limb girdle muscular dystrophy, type 1B; MAD, mandibuloacral dysplasia; MDC, Muscular 
dystrophy, congenital; MLF, Malouf  Syndrome.  
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1.6	 	 Post-Translational Lamin A Processing 
Mature lamin A is formed from a precursor protein called prelamin A. This protein must go 
through several post-translational steps in order to become mature lamin A (Figure 6). Lamin 
B1 and B2 also go through this process, however lamin C lacks a farnesylation site and 
therefore does not.30,48 
Prelamin A contains a CAAX box on exon 12 at the carboxyl terminus (Figure 5), this is a 
sequence of  amino acids which act as a target for a process known as farnesylation. The 
CAAX sequence is; C: Cysteine, A: an aliphatic amino acid, and X: any amino acid. In 
prelamin A the CAAX sequence is cysteine, serine, isoleucine and methionine (CSIM).  
This CSIM motif  is identified by farnesyltransferase and geranylgeranyltransferase-I and is 
modified and removed during lamin A maturation.49 
 
Figure 6. Lamin A processing. The maturation of  prelamin A to mature lamin A involves several 
steps, which in HGPS and RD are interrupted, resulting in the production of  progerin in HGPS and 
prelamin A in RD.58 Notably the accumulation of  progerin or other truncated prelamin A isoforms has 
also been found in RD.56  
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The posttranslational steps are outlined below;  
i. Farnesylation 
The CSIM-cysteine is farnesylated by farnesyltransferase (FTase). 
ii. Initial cleavage  
The last three CSIM amino acids, SIM, are removed by zmpste24 or RCE1.  
iii. Methylation 
The farnesylated cysteine is methylated by isoprenylcysteine carboxylmethyltransferase 
(ICMT), resulting in the localisation of  prelamin A to the INM.30,50-52 
iv. Terminal cleavage 
The terminal 15 amino acids are cleaved by zmpste24, producing mature lamin A. 
1.7	 	 Post-Translational Lamin A Processing In HGPS And RD 
The aberrant processing of  prelamin A in HGPS and RD is shown in figure 6. In HGPS, a 
cryptic splice site is activated, resulting in the loss of  150 nucleotides from prelamin A mRNA. 
This results in a translated protein that lacks the 50 amino acids containing the recognition 
site for zmpste24 (which is the RSYLLG motif). As a result, the terminal cleavage step fails to 
occur and the farnesylated, carboxymethylated C-terminus is retained. The resultant mutant 
protein is found attached to the INM and is known as farnesylated prelamin AΔ50, lamin 
AΔ50 or simply, progerin.3,30,53-55  
RD is caused most often by loss of  function mutations in ZMPSTE24 (which encodes 
zmpste24, the enzyme that catalyses the final cleavage step in prelamin A processing), causing 
prelamin A accumulation (Figure 6).56 The disease can also be caused by heterozygous 
mutations in the LMNA gene (c.1824C>T) or c.1968+1G>A. These mutations resulted in the 
partial or complete loss of  exon 11, which holds the recognition site for zmpste24, also 
leading to prelamin A accumulation.56,57 The increased severity of  RD cases where LMNA is 
mutated might be caused by increased levels of  progerin compared to HGPS.59 The very 
severe symptoms in RD patients might also suggest that the zmpste24 enzyme has other 
targets in addition to lamin A. Proteins with the CAAX motif  are involved in many cellular 
functions such as proliferation, differentiation, and carcinogenesis. 
Cultured HGPS patient cells have been shown to accumulate progerin in an age-dependent 
manner,60,61 correlating with more severe structural changes and a reduced growth rate.60 
Studies have been performed to examine if  progerin is also connected to normal ageing, and 
these studies revealed that not only was progerin found in normally aged individuals,62 but 
skin biopsy tests showed levels increased with age.63 In vitro studies showed that as fibroblasts 
age in culture, the amount of  mutated protein or mRNA increases with the number of  
passages.64,65 These results suggest that the presence and accumulation of  progerin might 
contribute to normal physiological ageing.  
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Figure 7.  HGPS patient skin fibroblasts. Healthy (left) and HGPS patient (middle) skin fibroblasts, 
with a detailed view of  the diseased nuclei on the right. Immunofluorescent (IF) staining shows 
progerin in black, DNA in yellow, mitochondria in red and the endoplasmic reticulum in blue. 
1.8	 	 The Cellular Effects Of  HGPS 
HGPS patient cells exhibit irregularly shaped nuclei (Figure 7), which get more effected as the 
cells age in culture, demonstrating the accumulation of  progerin goes hand-in-hand with 
increased toxic effects.3,60 Progerin disrupts the functions of  lamin A and the lamina, and 
insoluble progerin aggregates in the INM causing the formation of  blebs in the NE, thickened 
lamina and loss of  peripheral heterochromatin.60 Normally lamin A/C mediates the 
peripheral location of  chromatin during differentiation, while lamin B receptor (LBR) does so 
during early development.66 
The changes bought about by progerin are thought to cause abnormal transcription and a 
high level of  misregulated genes.67 In vitro experiments with progerin-expressing human 
mesenchymal stem cells resulted in abnormal differentiation of  the cells into bone- and 
adipose-related cell types.68 Cells expressing progerin also show a mislocalisation and 
clustering of  NPCs, which is thought to impair the normal movement of  proteins and mRNA 
into and out of  the nucleus.60 Defects in genomic stability with an increased level of  double-
strand breaks have also been shown in HGPS studies.69,70  
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1.9	 	 The Skin  
The skin is the first place where symptoms are visible in HGPS, and a tight and relatively 
inelastic skin is the cause of  death for RD patients. Therefore skin is the organ chosen for 
study in Papers I and II. It is the largest organ in the body, and serves several important 
functions. As a tough and watertight barrier, it protects the body from pathogens, 
dehydration, as well as mechanical and chemical damage. It also contains a variety of  nerve 
endings which allow for sensation of  touch, pressure, pain and temperature. Skin also 
thermoregulates the body, with heat conservation aided by hair and subcutaneous adipose 
tissue, and heat loss aided by sweat glands and dilated blood vessels. The skin is composed 
primarily of  three layers; the epidermis, dermis and hypodermis.71 
The epidermis is the outermost layer and interfaces with the environment. It consists of  
approximately 95% keratinocytes (Figure 8), with Merkel cells, Langerhans cells and 
melanocytes making up the remainder. The thicker dermal layer underlies and supports the 
epidermis, and is composed of  fibroelastic tissue. It contains many sensory receptors, and is 
highly vascular. Finally beneath the dermis is the hypodermis, which contains mainly adipose 
tissue. 
There are extensive prior studies on skin which provide many tools for the examination of  the 
well characterised stem cell population in skin. 
Figure 8. The epidermis. IF is used to differentiate keratinocytes, which are labelled in blue. DNA is 
yellow and lamin B1 is red. Some non-keratinocytes can be seen in the epidermis labelled in red, these 
could be Merkel or Langerhans cells. The layers of  the skin are listed on the right. 
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The epidermis is made up of  the following layers (listed from the lower to upper layers)72,73;  
i. Stratum basale (basal layer) 
The epidermis is constantly renewed by the division of  a layer of  stem cells in the basal 
layer. As the daughter cells detach from the basement membrane and migrate towards 
the skin surface, they change shape and lose their proliferative potential. 
ii. Stratum spinosum (spinous layer)  
As the cells migrate into the spinous layer, they begin to cornify, that is they begin to 
produce keratins and other proteins as well as begin to lose their nuclei and organelles. 
Keratins are very tough, fibrous proteins that make up the bulk of  hair, nails and the 
outer layer of  skin. 
iii. Stratum granulosum (granular layer) 
In this layer the cells become more cornified, and the cells also secrete lamellar bodies 
into the extracellular matrix (ECM), forming a hydrophobic barrier. Programmed cell 
death occurs. 
iv. Stratum corneum (horny layer) 
The outermost layer of  skin consists of  15-20 layers of  dead, flattened cells, which are 
continually shed, and continually replaced by the cells of  the inner layers migrating 
outward. 
Notably, the epidermis in mice from postnatal day 5 onwards has a depth of  only one cell 
layer. This is markedly different from mature human skin which has a thickened appearance. 
However when progerin is expressed in keratinocytes using the K5tTA promoter, the skin 
undergoes a striking hyperplasia which causes it to become thicker (Figure 8).  
1.10		 Adult Stem Cells 
The segmental tissue specificity of  HGPS seems to selectively affect tissues that undergo 
continuous growth and regeneration such as hair follicles, as well as tissues that undergo high 
levels of  mechanical stress (such as joints, or cardiac blood vessels). These tissues have specific 
caches of  continuously proliferating adult stem cells. Indeed, tissues which are more 
independent of  the need for continuous regeneration, and those tissues that are protected 
from mechanical stress, seem to be less affected or even unaffected in HGPS (such as the 
brain, or liver).74 This hypothesis is supported by in vitro studies where progerin expression 
induced differentiation in human mesenchymal stem cells.75 In another study using induced 
pluripotent stem cells from HGPS patients suggested that the exhaustion of  mesenchymal 
stem cells could be the cause of  increased hypoxia sensitivity.76  
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1.11		 Animal Models 
In 1974 the first genetically modified animal was created when a DNA virus was introduced 
into a mouse embryo, resulting in the inserted genes being present in all cells of  the animal.77 
In 1981 the first mouse model was developed that transmitted the exogenous genetic material 
to following generations.78 The transgenic mouse has since proven to be an invaluable tool for 
medical research, with models developed for the study of  many diseases, such as heart disease, 
arthritis and ageing. 
The first transgenic mouse model specific for HGPS was published in 2006 by random 
integration of  a human bacterial artificial chromosome (BAC) with the c.1824C>T LMNA 
mutation to a mouse-line. Both human lamin A/C and progerin were overexpressed in all 
tissues of  these mice, however they lacked the gross pathologic features of  HGPS. The mice 
did however lose vascular smooth muscle cells (VSMCs) in the medial layer of  large arteries, 
as seen in HGPS patients, although this had no effect on their life expectancy.79 
A progeriod mouse model with mechanistic similarities to RD was developed by completely 
knocking out the zmpste24 gene,50 resulting in the accumulation of  farnesylated prelamin A at 
the INM. These mice appear normal at birth, but thereafter develop skeletal abnormalities 
with spontaneous bone fractures, abnormal teething, progressive hair loss and muscle 
weakness. They die prematurely at the age of  6-7 months.80,81  
The recently created knock-in lmnaG609G mouse model had the wild-type mouse lmna gene 
replaced with a copy containing the murine equivalent of  the human HGPS LMNA c.
1824C>T, p.G608G mutation, which is lmna c.1827C>T, p.G609G. These mice had clinical 
features that were very similar to those found in HGPS. They accumulate progerin, displayed 
growth retardation, weight loss, bone abnormalities, cardiovascular problems and had a 
shortened lifespan.91  
During the last decade many other mouse models have been developed targeting prelamin A 
processing or with various mutations in the lmna gene.82,83 In our lab we have focused on 
tissue specific inducible mouse models expressing the LMNA c.1824C>T, p.G608G mutation. 
This is detailed in section 1.13.  
1.12		 The Control System 
In order to study one of  the most fascinating aspects of  HGPS, the segmental phenotype, a 
mouse model with tetracycline controlled gene expression was used. These model systems can 
control transgenic expression spatially, by using a tissue specific promoter, and temporally, by 
adding or removing the tetracycline derivative, doxycycline (dox). This powerful binary 
control system allows for the deliberate and controlled expression of  a protein in restricted 
tissues, at regulated time-points (Figure 9).84,85 With this control system studies can be 
performed on mature animals even when gene products would be lethally toxic if  expressed 
in embryogenesis. The effects of  transgene expression in specific tissues can also be examined, 
and even the possibility of  disease reversal can be studied by ceasing the expression of  the 
protein after the disease phenotype has been developed.  
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Two control elements define the system, the regulatory and the response elements. A tissue 
specific promoter controls the expression of  the regulatory element, either a tTA or an rtTA 
protein (corresponding to the Tet-Off  or Tet-On systems). The response part is a tetop 
element which is upstream from the target transgene. When a cell contains both elements, the 
gene of  interest is expressed once the tTA/rtTA element binds to the tetop motif.  
The difference between the Tet-on and Tet-off  system is that in the former, the rtTA molecule 
binds when tetracycline is present, and in the latter the tTA molecule binds when tetracycline 
is absent.84,85 We have used the Tet-off  system in Papers I and II, and the Tet-on system in 
Paper III. In order to study the effects of  progerin expression on skin, the K5 promoter was 
used in Papers I and II, and to study the effects on the cardiovascular system the sm22α 
promoter was used in Paper III.  
1.13		 The Minigene 
A human lamin A minigene using the Tet-system was generated to study the effects of  
progerin expression (Figure 9).86 It consists of  exons 1-11, intron 11 and exon 12 of  the 
human LMNA gene, followed by an internal ribosomal entry site (IRES), and the coding 
region of  enhanced green fluorescent protein (eGFP). The IRES allows for independent 
translation of  eGFP. The minigene terminates with an SV40/poly A tail to aid in nuclear 
export, mRNA stability and translation. On codon 608 the construct carries the most 
common HGPS c.1824C>T, p.G608G mutation (tetop-LAG608G).86 Mice with this 
minigene were crossed to mice with the K5 (Paper I and II) and the sm22α (Paper III) 
transactivators.87-89  
As skin is the first organ to display a typical disease phenotype in HGPS, and as it undergoes 
such extreme effects including scleroderma, loss of  subcutaneous fat and alopecia, the K5 
promoter was chosen to direct minigene expression to the basal cells of  the interfollicular 
epidermis and the hair follicle. In the K5tTA model the tetop-LAG608G+; K5tTA+ mice 
successfully expressed human lamin A and progerin in basal cells of  the interfollicular 
epidermis, (as well as in ameloblasts, and in the basal epithelia of  salivary glands, oesophagus, 
stomach, tongue, nose cavity and trachea).87 These mice were used to study postnatal 
expression in Paper I, and had expression from both postnatal day 0 and 21. In Paper II 
expression was induced embryonically in order to assess the mouse model as a model for RD.  
The organs of  the cardiovascular system are severely affected in HGPS, they undergo a 
progressive depletion of  vascular smooth muscle cells, and most often death from HGPS is 
caused by cardiovascular disease and complications due to atherosclerosis. The sm22α model 
was designed to express the minigene in vascular smooth muscle cells to allow for a detailed 
study of  the effects of  progerin on these cells, however no expression was detected. This is 
detailed in Paper III.  
Figure 9. The Tet systems (Opposite page). In the Tet-systems gene expression is controlled by 
administration of  doxycycline (dox). In the tTA (Tet-Off) system transcription is activated in the 
absence of  dox. In the rtTA (Tet-On) system transcription is activated in the presence of  dox. 
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1.14		 Treatment for HGPS 
As an autosomal dominant disease, HGPS would require gene therapy with anti-sense oligo 
morpholinos to target the splice site, as the production or effect of  progerin would need to be 
eliminated. Antisense oligonucleotides directed against the aberrant exon 11 and exon 12 
junction found in mutated pre-mRNAs, or the lamin A splice donor site found in exon 10, 
have been tested in HGPS cell lines, with positive results.90,91 However these treatments are 
not yet ready for clinical trials. 
A phase II clinical trial used a farnesyltransferase inhibitor (FTI) as treatment, which works by 
inhibiting the farnesylation of  prelamin A.7 Previous in vitro research with FTIs showed a 
significant reduction in the numbers of  misshapen nuclei.92 In vivo results were also impressive, 
with various HGPS and zmpste24-deficient mouse models showing an improvement in 
disease phenotype.93-98 However the disease was not completely cured by FTIs. Although FTI 
treatment inhibits the farnesylation of  prelamin A by farnesyltransferase, another 
modification pathway (via geranylgeranyltransferase-I) allows prelamin A to be processed into 
progerin despite the FTI.95 
The combination of  statins and bisphosphonates was used to inhibit the synthesis of  farnesyl 
pyrophosphate, which is a co-substrate of  farnesyltransferase and a substrate precursor for 
geranylgeranyltransferase-I. This combination resulted in increased lifespan, reduced 
oxidative stress, reduced cellular senescence and an improved phenotype in mouse models of  
laminopathies.96,99  
The positive outcomes from these studies lead to clinical trials in HGPS patients, which 
generated promising results, including improvement of  the vascular stiffness. However there is 
still a need to assess complementary treatments.100,101 
HGPS cells treated with rapamycin, which has been used in transplant patients as an anti-
rejection drug, showed enhanced progerin degradation, reduced levels of  senescence, and 
decreased levels of  nuclear blebbing.102-104 The enzyme ICMT has also been shown to be a 
potential target for progeria treatment, with beneficial effects in a progeria mouse model.105 
Additionally, treatment of  zmpste24 knock-out mice with resveratrol arrested their loss of  adult 
stem cells, slowed down body-weight loss, improved bone abnormalities and mineral density, 
as well as significantly extending the life span.106   
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2. 	Aims Of  The Thesis 
The aim of  this thesis was to increase the understanding of  the molecular mechanisms 
behind HGPS and RD, with a focus on skin and the cardiovascular system.  
Paper I.  
To test the hypothesis that premature exhaustion of  adult stem cells contributes to the 
progressive phenotype.  
Paper II.  
To test the hypothesis that the more severe phenotype in RD compared to HGPS is due to 
higher levels of  farnesylated prelamin A or progerin.  
Paper III.  
To develop a mouse model with tissue-specific expression of  the progeria mutation in vascular 
smooth muscle cells, and to examine the effects of  this expression.  
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3.	 Results and discussion 
3.1		 Paper I 
We induced expression of  the LMNA c.1824C>T, p.G608G HGPS mutation in mice with the 
K5 transactivator. Expression was induced from the date of  birth (D0), or from three weeks 
after birth (D21). The D0 mice exhibited a more severe and rapid progression of  the 
phenotype than D21 animals.  
The stem cell population in skin can be identified with a label-retention experiment, where 
animals are given Bromodeoxyuridine (BrdU) injections. BrdU is a thymidine analogue that is 
incorporated into newly synthesised DNA during cell division. After a series of  injections 
almost all epidermal cells are labeled. As the cells divide, the BrdU labels grow weaker, and 70 
days after the final injection, only cells that rarely divide still retain their BrdU labels. This 
label retention is an indicator of  the level of  cell division each cell has undergone. As stem 
cells are slow cycling by definition, cells that were still BrdU labelled after 70 days were 
considered to be stem cells.107 BrdU can also be used with a short chase period to identify 
actively proliferative cells. The animals are injected with a dose of  BrdU one hour before the 
tissue is collected. The BrdU is incorporated into dividing cells and marks them as 
proliferating cells.  
Figure 10. Epithelial label-retaining cells. IF skin sections with BrdU labelled cells shown in red and 
keratin 5 in blue. On the left a short chase period was used, and BrdU incorporation highlights 
proliferating cells along the edge of  a four-day-old wound. On the right a long chase was used, and 
BrdU marks slow cycling cells in a hair follicle. 
Using long-chase BrdU to identify stem cells, we showed that the progeria mice had a reduced 
population of  adult stem cells in dorsal skin. This was confirmed with fluorescence-activated 
cell sorting using two markers (α6-integrin and CD34) that have been shown to mark cells 
with stem cell characteristics. Further tests assessed the ability of  keratinocytes to form 
colonies in vitro. Stem cells should form large self-renewing colonies, while non-stem cells 
divide only a small number of  times before undergoing terminal differentiation.  
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Keratinocytes from progeria animals produced fewer colonies that were smaller and less dense 
compared to wild-type colonies. Additionally, stem cell markers Lrig1, CD34, and Krt15 were 
analysed with quantitative RT-PCR, and were seen to be downregulated in progeria mice.  
Epidermal adult stem cells are of  paramount importance in the tissue formation stage of  
wound healing, when cellular proliferation and migration close the open wound. To study this 
aspect of  wound healing, skin biopsies were taken and the wound site was analysed four and 
seven days post-wounding. Four-day-old wild-type wound edges had well organised 
proliferation and migration and after seven days were completely re-epithelialised. The 
wound edges in progeria animals were uneven and disorganised after four days and there 
were still wounds that were not re-epithelialised after seven days.  
Short-chase BrdU was used to identify proliferating cells in the wound edges. Progeria 
animals showed a significantly higher number of  BrdU-labeled cells compared to wild-type, 
seven days after wounding. However, progeria keratinocytes showed an impaired migration, 
delaying the wound healing relative to wild-type animals. The impaired keratinocyte 
migration could be the result of  reduced integrin expression. Transcripts from progeria and 
wild-type keratinocytes were analysed to test this. The results showed reduced expression of  
β1-integrin and α6-integrin in cells from progeria mice. 
DNA damage in keratinocytes was analysed with IF, using an antibody that can highlight 
double-stranded DNA breaks. Progeria mice had an increased frequency of  cells with higher 
amounts of  DNA double-strand breaks. This suggests that they had a higher number of  cells 
with severe DNA damage or that the cells had an impaired DNA damage repair mechanism. 
Severe or irreparable DNA damage is one trigger of  cellular senescence, which we examined 
with an assay for senescence-associated β-galactosidase. This test showed a tendency of  
increased senescence in the interfollicular epidermis of  progeria skin. 
It has been proposed that senescent cells secrete pro-inflammatory factors that cause 
surrounding cells to enter into a pro-inflammatory state. This set of  characteristics is termed 
the ‘‘senescence-associated secretory phenotype’’. We analysed selected inflammatory 
markers in keratinocytes from wild-type and progeria animals with quantitative RT-PCR. 
Progeria mice had a significant increase in all of  these markers. Senescence-associated 
secretory phenotype proteins are known to promote proliferation, and this matches the 
increased proliferation that is seen in this mouse model. Chronic inflammation is also known 
to impair stem cell function, and is associated with normal ageing, further supporting the 
correlation of  progerin expression and stem cell dysfunction and ageing. 
We also examined the expression of  p63, an epidermal stem cell maintenance protein, in the 
epidermis. It was downregulated on both the mRNA and protein level, which may account 
for the loss of  adult stem cells. The expression of  TAp63, an isoform of  p63, was also 
analysed in HGPS patients and was found to be downregulated.  
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3.2		 Paper II 
In order to ascertain if  the more severe symptoms in RD, as compared with HGPS, are due 
to the higher levels of  farnesylated lamin A or progerin produced in RD, the LMNA c.
1824C>T, p.G608G was expressed embryonically. IF examination of  skin from 17.5 day old 
embryos (E17.5) showed transgenic expression, using an antibody against human lamin A and 
progerin. The expression corresponded to keratin 5 positive skin cells. To quantify the levels 
of  expression Western blots were used, showing an increase in transgenic overexpression of  
lamin A, prelamin A, and progerin from E17.5 to D3 and to D5. RT-PCR comparing D8 to 
D5 showed that the transgenic expression of  progerin was unchanged, and the expression of  
lamin A was slightly reduced. This was reflected in an increased ratio of  progerin to lamin A. 
These results suggest that the increased levels of  progerin, lamin A, and prelamin A proteins 
were caused by their accumulation.  
The transgenic expression led to a severe phenotype with dry scaly skin, and death within the 
first two weeks of  life. Histological assessment of  dorsal skin sections showed no abnormalities 
at D3, but at D4 the wild-type animals showed the beginnings of  skin maturation, developing 
from a multilayered into single-layered epithelium, and this process was complete by D5. For 
animals expressing the mutation however, the skin maturation steps never took place, they still 
had the immature, multilayered epithelium. These animals showed a hyperplastic epidermis, 
disorganised sebaceous glands and an acute inflammatory dermal response at D5. By D9 the 
skin pathology was even more pronounced, with dense collagen fibres in the progeria animals 
that were not present in their wild-type littermates. These progeria animals had a diminished 
size, as well as hair thinning and dry scaly skin. There was no detected decrease in elastin, 
which is a histological feature seen in skin biopsies from RD patients. This is probably due to 
the mutation being expressed only in the epidermis, and not the dermis.  
The progeria animals were found to have a higher rate of  dehydration than their littermates, 
and a study of  their transepidermal water loss showed a significantly higher rate. The 
epidermal barrier function was tested, to check if  the skin could successfully prevent ingress 
of  a dye. The function of  tight junctions was also tested, these are a barrier found in the 
epidermis which prevent egress of  water from the skin (Figure 11). Both of  these systems were 
functional. The increased rate of  dehydration could be an effect of  the increased exposure 
area of  nucleated cells in a hyperplastic epidermis, as these cells lie outside the protection of  
the tight junctions. 
Another factor in the increased rate of  dehydration may be from the decreased efficacy of  
dry, cracked skin. Keratinocytes in progeria skin aberrantly retain intact nuclei (parakeratosis) 
instead of  undergoing terminal differentiation by transforming into corneocytes that lack 
nuclei (Figure 11). Corneocytes are filled with, covered with and release lipids. These lipids 
are necessary for healthy skin barrier function. The arrested development of  progeria 
keratinocytes may lead to a failure to maintain correct hydration of  the stratum corneum, as 
well as a failure to form a functional lipid matrix in the stratum corneum intracellular space.  
RT-PCR was also used to analyse inflammation effects in skin from progeria mice. Although 
no inflammatory response was seen at E17.5, by D3 multiple inflammatory response genes 
were upregulated, and this response was even more marked by D5.  
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Figure 11. Tight junctions. IF skin sections with the tight junction layer shown in red, progerin in 
blue and DNA in yellow. Hyperplasia, hyperkeratosis and parakeratosis are all clearly occurring.  
Cells from HGPS patients show a loss of  peripheral heterochromatin.60 The peripheral 
localisation of  heterochromatin during early development is thought to be mediated by LBR. 
As cells undergo terminal differentiation, this function is taken over by lamin A/C.66 Postnatal 
dorsal skin from progeria mice was analysed with IF using an antibody for LBR. D9 wild-type 
animals showed less LBR-positive cells compared with D3, in agreement with reduced 
expression of  LBR as development proceeds. For progeria animals, LBR-positive cells were 
found both in the basal and suprabasal cell layers.  
An analysis of  the DNA distribution in suprabasal LBR-positive cells of  D9 progeria animals 
showed a dense and depleted DNA distribution, with contiguous regions of  little or no DNA, 
a phenomena referred to as DNA condensation. Most suprabasal LBR-negative cells showed 
normal DNA distribution, with DNA dispersed in the intranuclear space. Notably a recent 
paper has indicated that induced chromatin condensation can stimulate damage-independent 
upstream signalling of  the DNA damage response (DDR), which in concert with these results, 
where an increased level of  DNA condensation was seen, might mean that indicators for 
double-strand breaks seen in Paper I do not necessarily imply the presence of  actual double-
strand breaks.108 
This unusual suprabasal LBR expression may be the cause for the failure of  keratinocytes to 
terminally differentiate, possibly by sequestering peripheral heterochromatin. Tightly 
regulated cytoplasmic and nuclear localisations, and chromatin association of  IKKa (the 
master kinase for NF-κB), are required for the activation of  the NF-κB pathway. So the 
disruption of  the nuclear lamina, as well as the loss of  peripheral heterochromatin in progeria 
cells may have lead to the inappropriate activation of  the NF-κB pathway. This NF-κB 
pathway activation may then have caused the observed inflammatory response. The 
expression of  the LMNA c.1824C>T mutation appears, in summary, to interfere with 
terminal cell differentiation, and to cause an arrest of  skin development possibly by the 
aberrant sustained expression of  LBR. Further studies are need to assess the contribution of  
LBR to the disease pathology.  
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3.3		 Paper III 
Death in HGPS is most often caused by complications from cardiovascular disease, including 
atherosclerosis, and a depletion of  vascular smooth muscle cells was seen in the cardiovascular 
system of  patients.14,15 In order to develop a mouse model that could further elucidate the 
mechanical mechanisms of  HGPS, as well as act as a testing platform for possible HGPS 
treatments, the LMNA c.1824C.T, p.G608G mutation was to be expressed in the vascular 
smooth muscle cells of  the aortic arch and thoracic aorta. The reverse tetracycline-controlled 
transactivator, sm22α-rtTA, was selected to control this expression.  
Tet-control systems are invaluable tools for disease studies. The ability to generate tissue 
specific mouse models while controlling the temporal expression of  target genes allows 
research on mature animals with gene products that would be lethal if  expressed during 
embryogenesis, expression in specific tissues can be examined, and stopping the protein 
expression after the disease phenotype has been developed allows for disease reversal to be 
studied. The sm22α-rtTA transactivator should have allowed us to direct the expression to the 
cardiovascular system with tissue specificity.  
However, the expression of  this transactivator was almost undetectable in the arteries, and 
was insufficient to induce the expression of  the minigene. RT-PCR using mRNA from the 
aortic arch showed only very weak amplification products for human lamin A, lamin AΔ150 
and the reverse transactivator after 35 cycles of  PCR. The same weak signal also came from 
samples that did not have the sm22α-rtTA transactivator. This would suggest that the weak 
amplification product occurred due to the leakiness of  the Tet-On and Tet-Off  models, which 
has been reported in previous studies.109-111 Protein extracts from pooled aortic regions were 
examined with an antibody for human lamin A/progerin on a Western blot, but did not show 
transgenic expression. 
The same antibody was used with IF to examine the aortic arches of  progeria animals, and 
only a very few transgene positive cells were found. IF analysis of  aortic arch tissue with an 
antibody against sm22α-actin failed to show any differences between the progeria animals 
and their wild-type littermates. Studies with haematoxylin and eosin staining, and 
immunohistochemical staining with an antibody against cleaved caspase 3, a marker for 
apoptosis, also showed no differences between the transgene positive animals and their 
littermates.  
As the sm22α-rtTA transactivator has been previously shown to induce target transgene 
expression in the aortic arch, abdominal aorta and thoracic aorta,89 we can only hypothesise 
that perhaps epigenetic modifications of  the promotor sequence of  the sm22α-rtTA transgene 
may have occurred, resulting in suppression of  the rtTA expression.111-113 
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3.4		 Future Perspectives 
Although the clinical trials in patients with HGPS have generated promising results, including 
improvement of  vascular stiffness, there is still a need to assess complementary treatments. 
The availability of  various animal models will be of  importance in the future assessment of  
options for treating HGPS, both treatments being discussed now but also new candidates that 
will emerge from ongoing research.  
Unpublished results from our laboratory with suppressed transgenic expression of  the HGPS 
mutation after a phenotype had been developed (in bone and skin) indicated an improved 
phenotype, suggesting that treatments targeting aberrant progerin splicing can help HGPS 
patients. The treatment of  zmpste24 -/- mice with resveratrol resulted in a significantly 
improved phenotype in addition to an increased life span compared to untreated mice.106 
This suggests that treatment with resveratrol in our tissue-specific HGPS bone model might 
be associated with a positive outcome.  
The results in papers I and II point towards an increased rate of  inflammation in the early 
stages of  progeroid skin pathology (evident already on postnatal day 3). Results from 
treatment with NF-κB inhibitors in progeroid mice have shown promising results,114 and our 
results support the notion that anti-inflammatory drugs might be good candidates for 
suppression of  certain aspects of  the progeroid disease phenotype.  
Our animal models could also be of  importance in the identification of  novel potential targets 
for the treatment of  progeria and ageing. Interestingly, when analysing the expression of  LBR 
in the interfollicular epidermis of  our progeria mice, we identified a significant fraction of  
suprabasal cells at postnatal day 9 with sustained LBR expression. These cells also showed an 
aberrant DNA distribution (Paper II). Future studies could use RNA sequencing to analyse 
early changes in gene expression that are induced by the expression of  the progeria mutation 
in LBR positive suprabasal keratinocytes. Primary keratinocytes would be extracted from 
progeria mice (and littermate controls) and sorted using FACS into populations of  suprabasal 
and basal keratinocytes. Then RNA would be extracted from these populations and processed 
for gene expression analysis. By taking this approach one might be able to identify early 
changes in gene expression. These would likely be primary effects preceding the pathological 
changes, which are not evident until postnatal day 4. This approach could potentially identify 
therapeutic targets for HGPS, and perhaps also physiological skin ageing. 
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